A Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine in Korean Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Soochurl | - |
dc.contributor.author | Lee, Soyoung Irene | - |
dc.contributor.author | Yoo, Hanik | - |
dc.contributor.author | Song, Dong Ho | - |
dc.contributor.author | Ahn, Dong-Hyun | - |
dc.contributor.author | Shin, Dong Won | - |
dc.contributor.author | Yum, Sun Young | - |
dc.contributor.author | Walton, Richard | - |
dc.contributor.author | Mendez, Luis | - |
dc.date.accessioned | 2021-08-12T05:27:25Z | - |
dc.date.available | 2021-08-12T05:27:25Z | - |
dc.date.issued | 2011-06 | - |
dc.identifier.issn | 1738-3684 | - |
dc.identifier.issn | 1976-3026 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/16496 | - |
dc.description.abstract | Objective This multicenter, randomized, open-label, parallel trial aimed to provide a detailed dose-response profile for atomoxetine in Korean pediatric outpatients with attention-deficit/hyperactivity disorder (ADHD). Methods Male and female outpatients aged 6-18 years with ADHD meeting symptom severity criteria of 1.5 standard deviations above age and gender norms on the ADHD Rating Scale-IV-Parent: Investigator-Administered and Scored (ADHDRS-IV-Parent: Inv), and a Clinical Global Impression-ADHD-Severity score >= 4 were randomized to atomoxetine (mg/kg/day) 0.2 fixed, 0.5 fixed or 0.5 (7 days), 0.8 (7 days) then 1.2 for 28 days. The primary efficacy measure was change in ADHDRS-IV-Parent: Inv total score after 6 weeks of atomoxetine treatment. Results 01153 randomized patients, 83.7% were male and mean age was 9.8 (SD +/- 2.4) years. The completion rate was 86.9%. A graded dose response was apparent with mean change in ADHDRS-IV-Parent: Inv total scores of -9.6, -12.3 and -14.5 with atomoxetine 0.2, 0.5 and 1.2 mg/kg/day, respectively (p=0.024 - F-test). Moreover, a greater reduction in ADHD symptoms, as assessed by mean change from baseline to endpoint CGI-S and mean CGI-ADHD-Improvement at endpoint, was also observed with increasing atomoxetine dose. More patients receiving atomoxetine 1.2 mg/kg/day reported >= 1 treatment-emergent adverse event/s (58.3%) compared with 0.5 (40.7%; p=0.11) or 0.2 mg/kg/day (29.4%; p=0.005). These were generally mild to moderate. Conclusion Atomoxetine was found to be safe and well tolerated at all doses administered in Korean pediatric ADHD patients, and 1.2 mg/kg/day was an efficacious dose in this population. Psychiatry Investig 2011;8:141-148 | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한신경정신의학회 | - |
dc.title | A Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine in Korean Pediatric Outpatients with Attention-Deficit/Hyperactivity Disorder | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4306/pi.2011.8.2.141 | - |
dc.identifier.scopusid | 2-s2.0-79960968540 | - |
dc.identifier.wosid | 000292416800010 | - |
dc.identifier.bibliographicCitation | PSYCHIATRY INVESTIGATION, v.8, no.2, pp 141 - 148 | - |
dc.citation.title | PSYCHIATRY INVESTIGATION | - |
dc.citation.volume | 8 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 141 | - |
dc.citation.endPage | 148 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001560630 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | DEFICIT HYPERACTIVITY DISORDER | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.subject.keywordPlus | ADOLESCENTS | - |
dc.subject.keywordPlus | ADHD | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | METHYLPHENIDATE | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordAuthor | ADHD | - |
dc.subject.keywordAuthor | Atomoxetine | - |
dc.subject.keywordAuthor | Dose response | - |
dc.subject.keywordAuthor | Korea | - |
dc.subject.keywordAuthor | Pediatric | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.